Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
37
PSTV Quote, Financials, Valuation and Earnings
Last price:
$0.57
Seasonality move
:
6.73%
Day range:
$0.56 - $0.58
52-week range:
$0.16 - $2.31
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
9.29x
P/B ratio:
15.77x
Volume:
1.9M
Avg. volume:
5.4M
1-year change:
-46.31%
Market cap:
$79.7M
Revenue:
$5.8M
EPS (TTM):
-$1.90
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PSTV
Plus Therapeutics, Inc.
|
$1.5M | -$0.04 | -1.06% | -93.96% | $7.16 |
|
CATX
Perspective Therapeutics, Inc.
|
$206.8K | -$0.32 | -9.65% | -37.91% | $12.3077 |
|
PMI
Picard Medical
|
-- | -- | -- | -- | -- |
|
VNRX
VolitionRX Ltd.
|
$715.6K | -$0.05 | 272.5% | -33.67% | $2.20 |
|
VTAK
Catheter Precision, Inc.
|
$310K | -$0.20 | 118.75% | -11.57% | -- |
|
XTNT
Xtant Medical Holdings, Inc.
|
$32.7M | -- | -2.42% | -100% | $1.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PSTV
Plus Therapeutics, Inc.
|
$0.58 | $7.16 | $79.7M | -- | $0.00 | 0% | 9.29x |
|
CATX
Perspective Therapeutics, Inc.
|
$2.8800 | $12.3077 | $214.1M | -- | $0.00 | 0% | 195.28x |
|
PMI
Picard Medical
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
VNRX
VolitionRX Ltd.
|
$0.25 | $2.20 | $30.7M | -- | $0.00 | 0% | 17.13x |
|
VTAK
Catheter Precision, Inc.
|
$1.68 | -- | $2.1M | 0.40x | $0.00 | 0% | 7.90x |
|
XTNT
Xtant Medical Holdings, Inc.
|
$0.78 | $1.50 | $108.6M | 76.08x | $0.00 | 0% | 0.85x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PSTV
Plus Therapeutics, Inc.
|
0.41% | -0.931 | 0.02% | 1.22x |
|
CATX
Perspective Therapeutics, Inc.
|
1.35% | 3.691 | 1.3% | 8.47x |
|
PMI
Picard Medical
|
-- | 0.000 | -- | -- |
|
VNRX
VolitionRX Ltd.
|
-48.16% | 2.566 | 15.4% | 0.04x |
|
VTAK
Catheter Precision, Inc.
|
68.63% | -0.348 | 537.37% | 0.41x |
|
XTNT
Xtant Medical Holdings, Inc.
|
39.2% | 2.955 | 35.76% | 1.08x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PSTV
Plus Therapeutics, Inc.
|
$1.3M | -$4.5M | -- | -- | -320.83% | -$2.6M |
|
CATX
Perspective Therapeutics, Inc.
|
-$566K | -$27.9M | -37.13% | -37.63% | -13330.62% | -$18.3M |
|
PMI
Picard Medical
|
-- | -- | -- | -- | -- | -- |
|
VNRX
VolitionRX Ltd.
|
$318.2K | -$5.1M | -- | -- | -813.17% | -$3.5M |
|
VTAK
Catheter Precision, Inc.
|
-$320K | -$3M | -79.27% | -192.05% | -1336.73% | -$2.2M |
|
XTNT
Xtant Medical Holdings, Inc.
|
$22M | $2.5M | 2.15% | 3.78% | 7.64% | $4.2M |
Plus Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns PSTV or CATX?
Perspective Therapeutics, Inc. has a net margin of -316.61% compared to Plus Therapeutics, Inc.'s net margin of -12425.36%. Plus Therapeutics, Inc.'s return on equity of -- beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.
Company Gross Margin Earnings Per Share Invested Capital PSTVPlus Therapeutics, Inc.93.84% -$0.04 $5.1M CATXPerspective Therapeutics, Inc.-270.81% -$0.35 $245.5M -
What do Analysts Say About PSTV or CATX?
Plus Therapeutics, Inc. has a consensus price target of $7.16, signalling upside risk potential of 1134.27%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 327.35%. Given that Plus Therapeutics, Inc. has higher upside potential than Perspective Therapeutics, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than Perspective Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PSTVPlus Therapeutics, Inc.3 0 0 CATXPerspective Therapeutics, Inc.12 1 0 -
Is PSTV or CATX More Risky?
Plus Therapeutics, Inc. has a beta of 0.823, which suggesting that the stock is 17.692% less volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.249%.
-
Which is a Better Dividend Stock PSTV or CATX?
Plus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Plus Therapeutics, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PSTV or CATX?
Plus Therapeutics, Inc. quarterly revenues are $1.4M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. Plus Therapeutics, Inc.'s net income of -$4.4M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Plus Therapeutics, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Plus Therapeutics, Inc. is 9.29x versus 195.28x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PSTVPlus Therapeutics, Inc.9.29x -- $1.4M -$4.4M CATXPerspective Therapeutics, Inc.195.28x -- $209K -$26M
-
Which has Higher Returns PSTV or PMI?
Picard Medical has a net margin of -316.61% compared to Plus Therapeutics, Inc.'s net margin of --. Plus Therapeutics, Inc.'s return on equity of -- beat Picard Medical's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PSTVPlus Therapeutics, Inc.93.84% -$0.04 $5.1M PMIPicard Medical-- -- -- -
What do Analysts Say About PSTV or PMI?
Plus Therapeutics, Inc. has a consensus price target of $7.16, signalling upside risk potential of 1134.27%. On the other hand Picard Medical has an analysts' consensus of -- which suggests that it could fall by --. Given that Plus Therapeutics, Inc. has higher upside potential than Picard Medical, analysts believe Plus Therapeutics, Inc. is more attractive than Picard Medical.
Company Buy Ratings Hold Ratings Sell Ratings PSTVPlus Therapeutics, Inc.3 0 0 PMIPicard Medical0 0 0 -
Is PSTV or PMI More Risky?
Plus Therapeutics, Inc. has a beta of 0.823, which suggesting that the stock is 17.692% less volatile than S&P 500. In comparison Picard Medical has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock PSTV or PMI?
Plus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Picard Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Plus Therapeutics, Inc. pays -- of its earnings as a dividend. Picard Medical pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PSTV or PMI?
Plus Therapeutics, Inc. quarterly revenues are $1.4M, which are larger than Picard Medical quarterly revenues of --. Plus Therapeutics, Inc.'s net income of -$4.4M is higher than Picard Medical's net income of --. Notably, Plus Therapeutics, Inc.'s price-to-earnings ratio is -- while Picard Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Plus Therapeutics, Inc. is 9.29x versus -- for Picard Medical. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PSTVPlus Therapeutics, Inc.9.29x -- $1.4M -$4.4M PMIPicard Medical-- -- -- --
-
Which has Higher Returns PSTV or VNRX?
VolitionRX Ltd. has a net margin of -316.61% compared to Plus Therapeutics, Inc.'s net margin of -862.39%. Plus Therapeutics, Inc.'s return on equity of -- beat VolitionRX Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PSTVPlus Therapeutics, Inc.93.84% -$0.04 $5.1M VNRXVolitionRX Ltd.50.73% -$0.05 -$24.7M -
What do Analysts Say About PSTV or VNRX?
Plus Therapeutics, Inc. has a consensus price target of $7.16, signalling upside risk potential of 1134.27%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.20 which suggests that it could grow by 780%. Given that Plus Therapeutics, Inc. has higher upside potential than VolitionRX Ltd., analysts believe Plus Therapeutics, Inc. is more attractive than VolitionRX Ltd..
Company Buy Ratings Hold Ratings Sell Ratings PSTVPlus Therapeutics, Inc.3 0 0 VNRXVolitionRX Ltd.4 2 0 -
Is PSTV or VNRX More Risky?
Plus Therapeutics, Inc. has a beta of 0.823, which suggesting that the stock is 17.692% less volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.258, suggesting its more volatile than the S&P 500 by 25.804%.
-
Which is a Better Dividend Stock PSTV or VNRX?
Plus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Plus Therapeutics, Inc. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PSTV or VNRX?
Plus Therapeutics, Inc. quarterly revenues are $1.4M, which are larger than VolitionRX Ltd. quarterly revenues of $627.3K. Plus Therapeutics, Inc.'s net income of -$4.4M is higher than VolitionRX Ltd.'s net income of -$5.4M. Notably, Plus Therapeutics, Inc.'s price-to-earnings ratio is -- while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Plus Therapeutics, Inc. is 9.29x versus 17.13x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PSTVPlus Therapeutics, Inc.9.29x -- $1.4M -$4.4M VNRXVolitionRX Ltd.17.13x -- $627.3K -$5.4M
-
Which has Higher Returns PSTV or VTAK?
Catheter Precision, Inc. has a net margin of -316.61% compared to Plus Therapeutics, Inc.'s net margin of -1037.17%. Plus Therapeutics, Inc.'s return on equity of -- beat Catheter Precision, Inc.'s return on equity of -192.05%.
Company Gross Margin Earnings Per Share Invested Capital PSTVPlus Therapeutics, Inc.93.84% -$0.04 $5.1M VTAKCatheter Precision, Inc.-141.59% -$1.70 $21.3M -
What do Analysts Say About PSTV or VTAK?
Plus Therapeutics, Inc. has a consensus price target of $7.16, signalling upside risk potential of 1134.27%. On the other hand Catheter Precision, Inc. has an analysts' consensus of -- which suggests that it could grow by 2161.97%. Given that Catheter Precision, Inc. has higher upside potential than Plus Therapeutics, Inc., analysts believe Catheter Precision, Inc. is more attractive than Plus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PSTVPlus Therapeutics, Inc.3 0 0 VTAKCatheter Precision, Inc.0 0 0 -
Is PSTV or VTAK More Risky?
Plus Therapeutics, Inc. has a beta of 0.823, which suggesting that the stock is 17.692% less volatile than S&P 500. In comparison Catheter Precision, Inc. has a beta of -1.301, suggesting its less volatile than the S&P 500 by 230.084%.
-
Which is a Better Dividend Stock PSTV or VTAK?
Plus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Plus Therapeutics, Inc. pays -- of its earnings as a dividend. Catheter Precision, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PSTV or VTAK?
Plus Therapeutics, Inc. quarterly revenues are $1.4M, which are larger than Catheter Precision, Inc. quarterly revenues of $226K. Plus Therapeutics, Inc.'s net income of -$4.4M is lower than Catheter Precision, Inc.'s net income of -$2.3M. Notably, Plus Therapeutics, Inc.'s price-to-earnings ratio is -- while Catheter Precision, Inc.'s PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Plus Therapeutics, Inc. is 9.29x versus 7.90x for Catheter Precision, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PSTVPlus Therapeutics, Inc.9.29x -- $1.4M -$4.4M VTAKCatheter Precision, Inc.7.90x 0.40x $226K -$2.3M
-
Which has Higher Returns PSTV or XTNT?
Xtant Medical Holdings, Inc. has a net margin of -316.61% compared to Plus Therapeutics, Inc.'s net margin of 3.93%. Plus Therapeutics, Inc.'s return on equity of -- beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.
Company Gross Margin Earnings Per Share Invested Capital PSTVPlus Therapeutics, Inc.93.84% -$0.04 $5.1M XTNTXtant Medical Holdings, Inc.66.13% $0.01 $82.9M -
What do Analysts Say About PSTV or XTNT?
Plus Therapeutics, Inc. has a consensus price target of $7.16, signalling upside risk potential of 1134.27%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 93.3%. Given that Plus Therapeutics, Inc. has higher upside potential than Xtant Medical Holdings, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than Xtant Medical Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PSTVPlus Therapeutics, Inc.3 0 0 XTNTXtant Medical Holdings, Inc.2 0 0 -
Is PSTV or XTNT More Risky?
Plus Therapeutics, Inc. has a beta of 0.823, which suggesting that the stock is 17.692% less volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.052, suggesting its less volatile than the S&P 500 by 105.153%.
-
Which is a Better Dividend Stock PSTV or XTNT?
Plus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Plus Therapeutics, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PSTV or XTNT?
Plus Therapeutics, Inc. quarterly revenues are $1.4M, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Plus Therapeutics, Inc.'s net income of -$4.4M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Plus Therapeutics, Inc.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 76.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Plus Therapeutics, Inc. is 9.29x versus 0.85x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PSTVPlus Therapeutics, Inc.9.29x -- $1.4M -$4.4M XTNTXtant Medical Holdings, Inc.0.85x 76.08x $33.3M $1.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
